Research Uncovers Insights into Disease Progression in Coronary Artery Disease

A new study presented fresh data on the progression of coronary artery disease (CAD), a condition affecting millions worldwide. Researchers from the Department of Cardiology in Santander, Spain, conducted a retrospective, single-center, case-control study to determine whether antiphospholipid (aPL) and antinuclear antibodies (ANA) predict CAD progression. The study included 180 CAD patients and 210 matched controls, with the researchers analyzing autoantibodies such as anticardiolipin, anti-b2 glycoprotein I, anti-phosphatidylserine/prothrombin, and ANA.

Key Takeaways:

• The study aimed to determine the role of aPL and ANA in the progression of CAD, with a focus on patients classified as rapid clinical progressors (RCP) or long-standing stable (LSS).
• The researchers found that CAD patients more frequently exhibited positive aCL, but no significant association was found between aPL or ANA and CAD progression.
• The study included 180 CAD patients (58 RCP, 122 LSS) and 210 matched controls, with 180 (100%) of CAD patients and 198 (94.5%) controls exhibiting positive autoantibodies.
• The study found that CAD patients with positive aPL or ANA did not have a higher risk of disease progression compared to those without these autoantibodies.

Statistics:

• 180 CAD patients (58 RCP, 122 LSS) were included in the study.
• 210 matched controls were included in the study.
• 180 (100%) of CAD patients and 198 (94.5%) controls exhibited positive autoantibodies.
• The study found no significant association between aPL or ANA and CAD progression.

Sources:

• "Impact of antiphospholipid and antinuclear antibodies in coronary artery disease progression." (Frontiers in Immunology, 2025, 16. DOI: 10.3389/fimmu.2025.1632642)
• NewsRx. Studies Conducted at Department of Cardiology on Disease Progression Recently Published. Cardiovascular Week. November 3, 2025; p 120.